I-0483 for COVID-19
I-0483 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Recent Discovery of Triazine Derivatives as Protease Inhibitors for the Treatment of Coronavirus-19 (COVID-19), Current Organic Synthesis, doi:10.2174/1570179420666230320120852 ,
Abstract: The present application describes a class of compounds exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. The application also provides the synthesis of compounds and efficacy from in vitro and cell- based assays.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.